China Health Resource, Inc. Signs Second Consecutive Letter of Intent for Bulk DAR Purchase

Share Article

Second Letter of Intent guarantees increased DAR purchasing quantity for 2011, increasing yearly income for China Health Resource, Inc.

News Image

Dahurian Angelica Root

“Signing this second Letter of Intent not only signifies our dedication to continue producing high-quality Angelica, but it also reinforces our promising outlook for solid and successful growth over the next several years..."

Sichuan, PRC – Feb 22, 2011 – China Health Resource, Inc. (OTCBB: CHRI), a leading Chinese pharmaceutical company specializing in producing, processing and commercializing Dahurian Angelica Root (DAR), today officially announced the company has signed a Letter of Intent with Chengdu Longevity Church Business Co., Ltd, marking the company’s second consecutive Letter of Intent, which was previously signed with Sichuan Zhiyuan Aquarious Pharmacy Co., Ltd.

China Health Resource, Inc. is world-renowned for its high-quality Angelica in the native market of Sichuan, attracting both local and international dealers and pharmaceutical enterprises to work intimately with the company in a long-term agreement for the supply of Angelica. In addition, the company has gained great recognition for receiving GAP certification for Angelica production and exclusive use of the geographical logo, “Sichuan Angelica.”

“In our efforts to increase new developments and implementations for DAR, we, as a company, are focused on continuous growth and expansion,” stated Jiayin Wang, CEO, China Health Resource, Inc. “Signing this second Letter of Intent not only signifies our dedication to continue producing high-quality Angelica, but it also reinforces our promising outlook for solid and successful growth over the next several years as we continue to build lasting relationships with reputable companies within the pharmaceutical industry.”

Within the signed Letter of Intent between China Health Resource, Inc. and Chengdu Longevity Church Business Co., Ltd, the later has purchased 330 tons (300,000KG) of Angelica for 2011. As a result, China Health Resource, Inc. has secured over $800,000 USD (5,400,000 yuan) of additional income for 2011.

Additional information about China Health Resource, Inc. and Chengdu Longevity Church Business Co., Ltd can be found by visiting http://ChinaHealthResource.com.

About CHRI
China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the People's Republic of China. DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Press Contact:
Rebecca Binny-Hallmark
China Health Resource Inc.
(323) 403-3829
Rebecca(dot)hallmark(at)evotech(dot)com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rebecca Hallmark
Visit website

Media